ElucidVivo A.3 vs EchoNext
AI Verdict
Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you need detailed, quantitative analysis of arterial plaque composition and stability from CT angiography. This tool is ideal for stratifying patients with atherosclerosis and optimizing treatment decisions based on precise visualization and measurement of plaque characteristics, including Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, validated against histology.
View ElucidVivo A.3 →Choose EchoNext if…
Choose EchoNext if you require an AI-powered screening tool to detect hidden structural heart disease from standard ECGs. This is particularly useful for identifying risks of heart failure, valve disease, and pulmonary hypertension early, even before symptoms present, and can help determine which patients should undergo further evaluation with an echocardiogram.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | ElucidVivo A.3 | EchoNext |
|---|---|---|
| Pricing | Contact for pricing | Starts at $600/month |
| Deployment | Software application, likely on-premise or cloud-based (standard for medical imaging software, not explicitly detailed, but integrates with PACS/EMR). | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieBoth tools are FDA-cleared and designed for clinical use, implying a certain level of usability and integration into existing workflows. However, without specific details on user interface, training requirements, or integration complexities for either product beyond their deployment methods, it is difficult to definitively declare a winner. ElucidVivo A.3 integrates with PACS/EMR, while EchoNext is available through the OpenEvidence platform.
Clinical Value
TieBoth tools offer significant clinical value by addressing critical areas in cardiovascular health. ElucidVivo A.3 provides detailed quantitative analysis of arterial plaque, aiding in atherosclerosis patient stratification and treatment optimization. EchoNext, on the other hand, detects hidden structural heart disease from standard ECGs, offering broad screening capabilities for conditions like heart failure and valve disease. The 'winner' depends on the specific clinical need being addressed.
Pricing & Value
EchoNextEchoNext offers transparent tiered pricing starting at $600/month, with details on implementation fees and discounts, making its cost structure clear to potential buyers. ElucidVivo A.3's pricing is listed as 'contact for pricing,' which provides less immediate transparency for comparison. While the ultimate value depends on specific organizational needs and ROI, EchoNext's transparent pricing gives it an edge in this dimension.
Enterprise Readiness
EchoNextEchoNext explicitly states its target size, ranging from major hospitals to community practices, and offers tiered pricing plans including 'Custom' for larger schools with 500+ students annually, implying scalability and enterprise-level considerations. It also details custom enhancements and integrations. While ElucidVivo A.3 is expected to integrate with PACS/EMR, EchoNext's explicit mention of various organizational sizes and custom plans suggests a more clearly articulated enterprise readiness strategy.
Innovation
TieBoth tools demonstrate significant innovation in their respective domains. ElucidVivo A.3's AI-powered quantitative analysis of arterial plaque composition, validated against histology, represents a novel approach to atherosclerosis assessment. EchoNext's ability to detect hidden structural heart disease from standard ECGs, a widely available diagnostic tool, also showcases innovative application of AI for early detection. Both are pushing the boundaries of AI in cardiology.
Support & Docs
TieNeither the provided structured facts nor general web searches offer explicit details regarding the level of customer support, documentation, or training resources available for either ElucidVivo A.3 or EchoNext. Without this information, it is not possible to differentiate between the two tools in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | ElucidVivo A.3 | EchoNext |
|---|---|---|
| Name | ElucidVivo A.3 | EchoNext |
| Company | Elucid Bioimaging | Pathway Labs |
| Description | FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology. | FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features | AI-powered quantitative analysis of arterial plaque; Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Offers rotatable curved MPR vessel views and cross-sections; Aids in stratifying patients with atherosclerosis; Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity; Validated on ground-truth histology | AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support |
Videos
Demos, reviews, and walkthroughs featuring ElucidVivo A.3 and EchoNext.